MYR Pharmaceuticals在2019年AASLD波士顿会议上宣布多个演讲。

StephenW

MYR Pharmaceuticals Announces Multiple Presentations at the AASLD Meeting 2019 in Boston.

News provided by
MYR Pharmaceuticals

Nov 01, 2019, 18:33 ET

Share this article

BURGWEDEL, Germany, Nov. 1, 2019 /PRNewswire/ -- MYR Pharmaceuticals today announced the presentation of a number of results on bulevirtide at the upcoming meeting of American Association for the Study of Liver Diseases (AASLD), in Boston, US.

The results of 48 weeks administration of bulevirtide (Myrcludex), MYR`s first-in-class entry inhibitor for treatment of hepatitis B and D infection, will be presented:

    Heiner Wedemeyer, "Safety and Efficacy of 10 mg (high-dose) bulevirtide (myrcludex B) in combination with PEG-Interferon Alpha 2a or Tenofovir in patients with chronic HBV/HDV co-infection," oral presentation at the parallel Session HBV Therapeutics: New Agents, November 10, 2:00 pm.

Further data on bulevirtide will be presented by:

    Alessandro Loglio, "Long-term administration of 10 mg/day myrcludex B monotherapy in patients with HDV-related compensated cirrhosis in a real-life setting: effectiveness, safety and virus-host interactions," poster session Hepatitis: Other Infections, November 9, 2:00 pm

    Zhenfeng Zhang, "Synergistic suppression of HDV persistence in vitro by co-treatment with investigational drugs targeting both extracellular and cell division mediated spreading pathways," oral presentation at the Parallel session: HBV Virology, November 11, 5:00pm

An additional presentation on the long-term administration of bulevirtide will be given at the 18th Hepatitis Delta International Network (HDIN) Meeting during 2019 AASLD:

    Alessandro Loglio, "Effectiveness, safety and histological improvement of long-term administration of 10 mg/day myrcludex (bulevirtide) for HDV hepatitis: a case report of 3 patients," Sheraton Hotel, Gardner room, November 9, 9:15pm

"Bulevirtide demonstrated promising results in chronic hepatitis delta in Phase 2 clinical trials MYR202 and MYR203; the confirmatory clinical program is ongoing. The data presented during the AASLD meeting will provide new insights into the definition of optimal treatment regimens," said Alexander Alexandrov, Chief Medical Officer.

MYR Pharmaceuticals will be present with a scientific corner in Exhibition Hall, booth number 1206. Visit MYR Pharmaceuticals during the upcoming AASLD meeting from November 8th to 11th in Boston, USA, and arrange your personal appointment with our experts on site now.

About bulevirtide (Myrcludex)
Bulevirtide (Myrcludex) is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug inhibits the NTCP receptor on the hepatocyte surface and prevents the infection of healthy cells and viral spreading within the liver. Bulevirtide has received Orphan Drug Designation for treatment of HDV infection from the European Medicines Agency (EMA) and from the U.S. Food & Drug Administration (FDA). In addition, the EMA has granted PRIority MEdicines (PRIME) scheme eligibility - by this designation EMA offers early and proactive support for the development of medicines that target an unmet medical need.  In parallel the FDA has granted Breakthrough Therapy designation - a process designed to expedite the development and review of drugs which may demonstrate substantial improvements on a clinically significant endpoint. The British Medicines and Healthcare products Regulatory Agency (MHRA) has recently issued the Promising Innovative Medicine (PIM) designation for MYR's lead compound bulevirtide (Myrcludex).

About MYR Pharmaceuticals

MYR Pharmaceuticals is a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D virus infections. The company's lead compound bulevirtide is currently in Phase 3 clinical trial in the indication of chronic HDV infection.

StephenW

MYR Pharmaceuticals在2019年AASLD波士顿会议上宣布多个演讲。

新闻提供者
MYR制药

美国东部时间2019年11月1日18:33

分享此文章

2019年11月1日，德国布尔格维尔/ PRNewswire /-MYR制药公司今天在即将在美国波士顿举行的美国肝病研究协会（AASLD）会议上宣布了关于bulevirtide的多项研究结果。

将展示MYR的首个进入抑制剂，用于治疗乙型和丁型肝炎病毒感染的bulevirtide（Myrcludex）48周的治疗结果：

Heiner Wedemeyer，“在慢性HBV / HDV合并感染的患者中，将10 mg（大剂量）bulevirtide（myrcludex B）与PEG-干扰素Alpha 2a或Tenofovir联合使用的安全性和有效性”，在并行会议HBV治疗上口服：11月10日下午2:00的新特工。

关于布列维肽的进一步数据将通过以下方式提出：

Alessandro Loglio，“在现实生活中，长期服用每日10 mg的Myrcludex B单药治疗与HDV相关的肝硬化患者：有效性，安全性和病毒-宿主相互作用”，海报会，《肝炎：其他感染》，11月9日，下午2:00

张振峰：“通过与针对细胞外和细胞分裂介导的扩散途径的研究药物共同治疗，体外协同抑制HDV持久性”，在并行会议上的口头报告：HBV病毒学，11月11日，下午5:00

在2019年AASLD期间的第18届肝炎三角洲国际网络（HDIN）会议上将另外发表关于bulevirtide的长期给药的报告：

亚历山德罗·洛格里奥（Alessandro Loglio），“长期服用10 mg /日Myrcludex（bulevirtide）治疗HDV肝炎的有效性，安全性和组织学改善：3例病例报告”，喜来登酒店，加德纳厅，11月9日，晚上9:15

“ Bulevirtide在2期临床试验MYR202和MYR203中证明在慢性肝炎三角洲中有希望的结果；正在验证临床计划。AASLD会议期间提供的数据将为最佳治疗方案的定义提供新的见解，”首席亚历山大医务人员。

MYR Pharmaceuticals将在展厅的科学角出现，展位号1206。在即将于11月8日至11日在美国波士顿举行的AASLD会议期间，访问MYR Pharmaceuticals，并立即与我们的专家安排您的个人约会。

关于布列维肽（Myrcludex）
Bulevirtide（Myrcludex）是用于治疗慢性乙型和丁型肝炎感染的一流的进入抑制剂。该药物抑制肝细胞表面的NTCP受体，并防止健康细胞的感染和病毒在肝脏内的传播。 Bulevirtide已获得欧洲药品管理局（EMA）和美国食品药品管理局（FDA）颁发的用于治疗HDV感染的孤儿药称号。此外，EMA还授予了优先医学（PRIME）计划资格-通过此称号，EMA为针对未满足医疗需求的药物开发提供了早期和积极的支持。同时，FDA授予了突破性疗法称号-一种旨在加快药物开发和审查的过程，该过程可能会证明在临床上具有重要意义的终点方面有实质性改善。英国医药保健产品监管局（MHRA）最近发布了有前途的创新药物（PIM），用于MYR的领先化合物bulevirtide（Myrcludex）。

关于MYR制药

MYR Pharmaceuticals是一家德国生物技术公司，致力于开发用于治疗慢性乙型和丁型肝炎病毒感染的疗法，并将其商业化。该公司的领先化合物bulevirtide目前正在3期临床试验中，用于指示慢性HDV感染。